A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis
Latest Information Update: 16 Oct 2023
At a glance
- Drugs Olokizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms CREDO 4
- Sponsors R-Pharm
- 03 Jun 2023 Results assessing patient reported outcomes (PROs) from this long-term extension trial presented at the 24th Annual Congress of the European League Against Rheumatism
- 14 Nov 2022 Results presented at the ACR Convergence 2022
- 04 Jun 2022 Results reporting long-term safety and efficacy of Olokizumab in combination with methotrexate presented at the 23rd Annual Congress of the European League Against Rheumatism